GPCR

Structure Therapeutics Inc ADR

21.10

Oct 26 • 3:59 PM ET -0.09 (-0.42%)

21.04

Aftermarket • 7:30 PM ET -0.06 (-0.26%)

Healthcare Biotechnology USA Small NASD

Peers: VKTX KLRA SEPN ALT LLY NVO MDGL MLYS RYTM AMGN

| Held by: IBB SBIO SPEM FDG FFSM OZEM LRNZ ONEQ GXC APIE

Scroll to Statements

Index	-
Market Cap	1.50B
Enterprise Value	168.17M
Income	-215.18M
Sales	0.00M
Book/sh	19.02
Cash/sh	18.83
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	220
IPO	Feb 03, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.11
P/C	1.12
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	20.75
Current Ratio	20.75
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.08
EPS next Y	-2.15
EPS next Q	-0.33
EPS this Y	-108.19%
EPS next Y	-28.83%
EPS next 5Y	-
EPS past 3/5Y	-18.36% -40.35%
Sales past 3/5Y	- -
EPS Y/Y TTM	1.47%
Sales Y/Y TTM	-
EPS Q/Q	-36.11%
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-11.80% -

Insider Own	2.60%
Insider Trans	0.00%
Inst Own	90.22%
Inst Trans	1.15%
ROA	-19.20%
ROE	-20.24%
ROIC	-15.84%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.93%
SMA50	-41.29%
SMA200	-57.91%
Trades

Shs Outstand	71.22M
Shs Float	69.46M
Short Float	10.86%
Short Ratio	7.09
Short Interest	7.54M
52W High	94.90 -77.77%
52W Low	20.73 1.81%
Volatility	5.99% 6.05%
ATR (14)	1.57
RSI (14)	20.21
Beta	-1.23
Rel Volume	0.65
Avg Volume	1.06M
Volume	688,984

Perf Week	-4.13%
Perf Month	-41.27%
Perf Quarter	-55.94%
Perf Half Y	-53.45%
Perf YTD	-69.66%
Perf Year	-20.05%
Perf 3Y	-69.86%
Perf 5Y	-
Perf 10Y	-
Recom	1.12
Target Price	106.73
Prev Close	21.19
Price	21.10
Change %	-0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-26	Initiated	Canaccord Genuity	Buy	$101
Mar-26-26	Initiated	Wolfe Research	Peer Perform
May-02-25	Initiated	Citigroup	Buy	$60
Feb-28-25	Initiated	William Blair	Outperform
Jan-08-25	Initiated	Stifel	Buy	$50
Dec-04-24	Initiated	H.C. Wainwright	Buy	$80
Sep-23-24	Initiated	Morgan Stanley	Overweight	$118
May-21-24	Initiated	JP Morgan	Overweight	$65
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-19-23	Initiated	JMP Securities	Mkt Outperform	$90
Jul-27-23	Initiated	Piper Sandler	Overweight	$58
May-25-23	Resumed	Jefferies	Buy	$34 → $41
Feb-28-23	Initiated	SVB Securities	Outperform	$33
Feb-28-23	Initiated	Jefferies	Buy	$34
Feb-28-23	Initiated	Guggenheim	Buy	$50
Feb-28-23	Initiated	BMO Capital Markets	Outperform	$40

Show Previous Ratings

Oct-19-26 04:13PM	Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2026 (GlobeNewswire)
Sep-23-26 08:30AM	Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) (FinanceWire)
Sep-22-26 01:29AM	VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 Multi-Blockbusters (Stocktwits)
Sep-08-26 08:00AM	Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management (GlobeNewswire) -14.70%
Sep-03-26 07:30AM	Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Aug-06-26 04:05PM	Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights (GlobeNewswire)
Jun-06-26 02:53PM	Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy. (MarketWatch)
Jun-05-26 04:05PM	Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity (GlobeNewswire)
May-26-26 04:05PM	Structure Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-21-26 05:38AM	Lillys triple-acting obesity drug hits goal in Phase 3 trial (BioPharma Dive) +5.21%
May-07-26 04:05PM	Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights (GlobeNewswire)
Apr-27-26 04:05PM	Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire)
Apr-14-26 04:05PM	Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel (GlobeNewswire)
Mar-17-26 03:20PM	This biotech is working on a GLP-1 pill that could be better than the Wegovy version (MarketWatch)
09:15AM	Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk (Proactive)
04:12PM	Loading…
Mar-16-26 04:12PM	Structure Therapeutics Pops; But Can It Take On Lilly's Looming Obesity Pill? (Investor's Business Daily) +5.40%
10:46AM	Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate? (Barrons.com)
07:35AM	Structures GLP-1 pill shows best-in-class potential in obesity trial (BioPharma Dive)
07:00AM	Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron (GlobeNewswire)
Mar-05-26 08:12AM	Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? (Zacks) -5.43%
Feb-26-26 04:02PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights (GlobeNewswire)
Feb-25-26 08:40AM	Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead? (Zacks)
Feb-24-26 12:00PM	Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 (Zacks)
Feb-23-26 01:25PM	Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin (Investor's Business Daily)
Feb-19-26 06:58AM	Structure Therapeutics (GPCR) Gained from Favorable Clinical Data (Insider Monkey)
Feb-18-26 07:22AM	Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? (Zacks)
Feb-12-26 08:42AM	How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report (Zacks) -5.19%
Feb-10-26 10:49AM	Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026 (Zacks)
Feb-04-26 09:30AM	Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook (Zacks)
Jan-23-26 09:18AM	Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It (Benzinga)
12:13PM	Loading…
Jan-16-26 12:13PM	Jim Cramer on Structure Therapeutics: "I Don't Want to Touch It" (Insider Monkey)
10:47AM	LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling (Zacks)
Jan-15-26 11:35AM	Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why (Insider Monkey)
11:07AM	Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments (Benzinga)
10:17AM	How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results? (Zacks)
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-11-26 04:05PM	Can This Stock Double Again in 2026? (Motley Fool)
Jan-09-26 11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
09:58AM	VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug (Zacks)
Jan-08-26 09:12AM	H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 (Insider Monkey)
Jan-05-26 10:37AM	LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? (Zacks) -7.85%
Dec-24-25 10:49AM	NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly? (Zacks)
Dec-23-25 10:46AM	Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up (Zacks) +12.71%
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks)
Dec-17-25 08:30AM	Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (GlobeNewswire)
Dec-15-25 10:32AM	CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval (Zacks)
Dec-12-25 10:37AM	NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? (Zacks)
Dec-11-25 04:28PM	Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss (Investor's Business Daily)
04:01PM	Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs (GlobeNewswire)
10:23AM	Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge? (Zacks)
08:10AM	Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% (Investor's Business Daily)
Dec-10-25 10:17AM	Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? (Zacks)
Dec-09-25 11:15PM	Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants (GlobeNewswire)
02:23PM	Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial (Insider Monkey)
11:15AM	In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera? (Investor's Business Daily)
09:27AM	GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron (Zacks)
Dec-08-25 08:15PM	Why Structure Therapeutics Stock Doubled and Then Some on Monday (Motley Fool) +102.49%
04:15PM	Structure Therapeutics Soars; CEO Says It Could Have 'Best In Class' Weight-Loss Drug (Investor's Business Daily)
04:01PM	Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants (GlobeNewswire)
12:46PM	Obesity Biotechs' Gains Hit Shares of Eli Lilly, Novo Nordisk (Barrons.com)
10:36AM	Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill (The Wall Street Journal)
09:12AM	Structure details positive trial data for a weight-loss pill, and the stock rockets (MarketWatch)
08:00AM	Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 06:20PM	Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 (GlobeNewswire)
Nov-16-25 10:14PM	BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts (Insider Monkey)
Nov-06-25 04:01PM	Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Oct-30-25 02:11PM	Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. (Barrons.com) +8.96%
Oct-24-25 11:39AM	NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? (Zacks)
Sep-21-25 09:23AM	Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data (Insider Monkey)
Sep-12-25 08:15AM	This Under-the-Radar Healthcare Stock Could Soar in 2026 (Motley Fool)
Sep-02-25 08:30AM	Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-19-25 04:05PM	Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill (Investor's Business Daily) -5.81%
Aug-11-25 08:22PM	Structure Therapeutics To Present Late-Breaking ADA Data on Oral Amylin Agonist ACCG-2671 (Insider Monkey) +7.36% +7.02%
Aug-07-25 04:20PM	Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying (Investor's Business Daily)
09:55AM	Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors (Benzinga)
09:01AM	Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. (Investor's Business Daily)
Aug-06-25 04:01PM	Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Jun-24-25 05:42PM	Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT (Insider Monkey)
Jun-20-25 07:30PM	Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 (GlobeNewswire)
May-29-25 04:05PM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
May-08-25 04:05PM	Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Apr-25-25 04:31PM	Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts? (Insider Monkey)
Apr-21-25 08:37AM	LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study (Zacks) +6.16%
Apr-18-25 11:25AM	Eli Lilly jumps as results from weight-loss pill study rival competitors (TipRanks)
10:26AM	JPMorgan says Lilly data highly favorable for Structure Therapeutics (TipRanks)
Apr-15-25 10:35AM	Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill (TipRanks)
10:00AM	NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback (Zacks)
Apr-14-25 11:12AM	Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today (Motley Fool) +19.18%
Mar-24-25 07:21PM	Structure Therapeutics CEO on latest GLP-1 developments (CNBC TV)
Mar-20-25 09:28AM	Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate (SeekingAlpha)
Mar-03-25 04:20PM	AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. (Investor's Business Daily) -5.94%
Feb-27-25 04:05PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire) +14.79%
Feb-14-25 07:56AM	Why Structure Therapeutics Stock Was Stumbling This Week (Motley Fool)
Jan-30-25 08:30AM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
Dec-18-24 10:25AM	Merck Licenses a Weight-Loss Pill. Its Bad News for Obesity Biotechs. (Barrons.com) -11.37%
Dec-17-24 04:01PM	Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (GlobeNewswire)
Dec-16-24 01:33PM	Is Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-08-24 06:05AM	Jefferies Predicts Up to ~1000% Surge for These 2 Strong Buy Stocks (TipRanks)
Nov-27-24 10:15AM	Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts? (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BLAS COLL CRESPO	Officer	Sep 21 '26	Proposed Sale	35.00	4,008	140,280		Sep 21 04:35 PM
Lin Xichen	CHIEF SCIENTIFIC OFFICER	Sep 01 '26	Option Exercise	0.34	17,817	6,058	246,777	Sep 02 09:18 PM
Lin Xichen	CHIEF SCIENTIFIC OFFICER	Aug 18 '26	Option Exercise	0.34	11,817	4,018	240,777	Aug 19 08:23 PM
Lin Xichen	CHIEF SCIENTIFIC OFFICER	Aug 04 '26	Option Exercise	0.34	11,817	4,018	240,777	Aug 05 04:49 PM
Lin Xichen	CHIEF SCIENTIFIC OFFICER	Jul 14 '26	Option Exercise	0.34	23,634	8,036	252,594	Jul 15 06:57 PM
Lin Xichen	CHIEF SCIENTIFIC OFFICER	Jun 25 '26	Option Exercise	0.34	23,634	8,036	252,594	Jun 29 08:32 PM
XICHEN LIN	Officer	Jun 25 '26	Proposed Sale	48.16	35,512	1,710,258		Jun 25 04:27 PM

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

CEO & DirectorDr. Raymond C. Stevens Ph.D.

Co- FounderMr. Jun S. Yoon

Chief Technology OfficerDr. Yingli Ma Ph.D.

Chief Scientific Officer & GM of Structure ShanghaiDr. Xichen Lin Ph.D.

Ph.D.Dr. Blai Coll M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GPCR

Structure Therapeutics Inc ADR

Upgrade your Finviz experience